FL

Flerie ABSTO Flerie Stock Report

Last reporting period 30 Jun, 2024

Updated 19 Sep, 2024

Last price

Market cap $B

0.333

Micro

Exchange

XSTO - Nasdaq STOCKHOLM AB

FLERIE.ST Stock Analysis

FL

Uncovered

Flerie AB is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-45/100

Low score

Market cap $B

0.333

Dividend yield

Shares outstanding

78.066 B

Flerie AB is a SE-based company operating in Pharmaceuticals industry. The company is headquartered in Stockholm, Stockholm and currently employs 7 full-time employees. The company went IPO on 2016-10-11. Flerie AB, formerly InDex Pharmaceuticals Holding AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The firm is an active long-term global biotech and pharmaceutical investor that managing a portfolio of companies in Europe, Israel, and the US. Flerie invests in companies across the entire value chain, providing exposure to opportunities across three segments: Product Development, Commercial Growth, and Limited Partnerships. The Product Development segment consists of early-stage biotech and pharma companies in product development. The Commercial Growth segment consists of companies that are already selling products or services and showcasing proof-of-concept with high growth and some that have already reached profitability. The Limited Partnerships segment provides benefits for the other two segments, including co-investment opportunities, and derisks Flerie’s investment portfolio.

View Section: Eyestock Rating